News

Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer
Bristol Myers Squibb (NYSE:BMY) announced on Friday that its anemia therapy, Reblozyl, developed with Merck (NYSE:MRK), did ...